VERIGRAFT Secures $10M Financing From Existing Investors to Launch Pivotal Phase II/III Trial

Why It Matters

A curative, biologic solution for CVI could shift treatment from symptom management to disease reversal, opening a multi‑billion‑dollar market and setting a new standard for vascular regenerative therapies.

Key Takeaways

• P-TEV trial starts Phase II/III in Europe
• $10 million financing backs pivotal trial
• Fully biological vein graft avoids immunosuppression
• Market aims for US/EU approval by 2028
• CVI market projected $5.95 billion by 2034

Pulse Analysis

Chronic venous insufficiency affects millions worldwide, driven by aging populations, obesity, and sedentary lifestyles. Current interventions focus on compression therapy or invasive procedures that merely alleviate symptoms, leaving a sizable unmet need for a definitive cure. Analysts forecast the global CVI market to exceed $5.9 billion by 2034, reflecting both the disease’s prevalence and the limited therapeutic arsenal. This backdrop creates fertile ground for innovative regenerative approaches that can deliver lasting vascular repair.

VERIGRAFT’s personalized tissue‑engineered vein leverages decellularized donor veins re‑populated with the patient’s own blood components, producing a graft that integrates seamlessly without triggering immune rejection. The 10‑day manufacturing cycle, protected by 92 patents, enables rapid, scalable production that aligns with surgical timelines. By restoring functional venous valves, P‑TEV addresses the root cause of venous hypertension, promising true patency and hemodynamic normalization—advantages that differentiate it from stents, sclerotherapy, or laser ablation.

The company’s $10 million financing round underscores investor confidence in advanced therapy medicinal products (ATMPs) that combine personalized medicine with regenerative biology. With pivotal data expected to shape regulatory submissions in both the EU and the US by 2028, VERIGRAFT is positioned to attract partnership interest from major pharma and medical device firms seeking to expand their vascular portfolios. Successful approval could catalyze broader adoption of fully biological grafts across other vascular indications, reinforcing the trend toward curative, patient‑specific solutions in the biotech sector.

Deal Summary

Swedish biotech company VERIGRAFT announced it has raised $10 million from existing investors to fund the initiation of a pivotal Phase II/III trial of its personalized tissue‑engineered vein (P‑TEV) for chronic venous insufficiency. The financing will support trial sites in Spain, the Netherlands and Poland and aims to achieve market approval in Europe and the US by 2028.